Aditx, Inc. (ADTX)

Market Cap	7.03M
Revenue (ttm)	853,153
Net Income (ttm)	-43.52M
Shares Out	1.43M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	0.37
Dividend	n/a
Ex-Dividend Date	Sep 14, 2022

Volume	42,937
Open	1.67
Previous Close	1.67
Day's Range	1.61 - 1.67
52-Week Range	1.57 - 41.15
Beta	1.37
Analysts	Buy
Price Target	27.54 (+1,579.3%)
Earnings Date	Nov 21, 2022

About ADTX

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ trans...

• Industry: Biotechnology
• IPO Date: Jun 30, 2020
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: ADTX

Analyst Forecast

According to 8 analysts, the average rating for ADTX stock is "Buy." The 12-month stock price forecast is 27.54, which is an increase of 1,579.27% from the latest price.

Price Target

$27.54

(1,579.27% upside)

Analyst Consensus: Buy